Literature DB >> 27083331

Ponatinib for chronic myeloid leukaemia: future perspectives.

Carmen Fava1, Giuseppe Saglio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27083331     DOI： 10.1016/S1470-2045(16)30064-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Gene deficiency or pharmacological inhibition of PDCD4-mediated FGR signaling protects against acute kidney injury.

Authors:  Xu Jing; Dandan Ren; Fei Gao; Ye Chen; Xiao Wu; Yue Han; Qingsheng Han; Liang Li; Xiaojie Wang; Wei Tang; Yan Zhang
Journal:  Acta Pharm Sin B       Date:  2020-11-05       Impact factor: 11.413

2.  Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.

Authors:  Haoyu Li; Yongfeng Wang; Zhenghu Chen; Jiaxiong Lu; Jessie Pan; Yang Yu; Yanling Zhao; Huiyuan Zhang; Ting Hu; Qing Liu; Jianhua Yang
Journal:  Oncotarget       Date:  2017-01-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.